Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07433426
PHASE2

The Impact of Shigellosis and Recommended Treatment in Children

Sponsor: Johns Hopkins Bloomberg School of Public Health

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate whether antibiotic treatment of non-dysentery Shigella associated watery diarrhea (NDSD) cases improves clinical outcomes and growth in children. Children with NDSD seeking care for diarrhea at the study hospitals in Bangladesh and Zambia will be enrolled and randomized to receive Azithromycin or placebo (a look-alike substance that contains no drug). Enrolled children will be followed for three months with household visits. The investigators will determine whether antibiotic treatment of NDSD reduces the duration of diarrhea and time to microbiological cure (shedding of Shigella in stool), and whether it improves growth in children compared with the placebo group.

Key Details

Gender

All

Age Range

6 Months - 59 Months

Study Type

INTERVENTIONAL

Enrollment

700

Start Date

2026-03-18

Completion Date

2030-08

Last Updated

2026-03-30

Healthy Volunteers

No

Interventions

DRUG

Azithromycin

Azithromycin will be given as 10 mg/kg body weight once daily for 5 days

DRUG

Placebo

Placebo will be similar in appearance to the intervention but will contain inactive ingredients.

Locations (4)

icddr,b Matlab Hospital

Chāndpur, Bangladesh

icddr,b Hospital

Dhaka, Bangladesh

Matero Level 1 Hospital

Lusaka, Zambia

Arthur Davidson Children's Hospital

Ndola, Zambia